Press release
Locally Advanced Pancreatic Cancer Market to Reach New Heights in Growth by 2032, DelveInsight Predicts | AstraZeneca, R-Pharm, Hoffmann-La Roche, AB Science, Meabco A/S, Celgene, iOnctura, Tesaro, Inc., FibroGen, SynCore Biotechnology, Jiangsu HengRui Me
To Know in detail about the Locally Advanced Pancreatic Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Locally Advanced Pancreatic Cancer Market Forecast
https://www.delveinsight.com/sample-request/locally-advanced-pancreatic-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Locally Advanced Pancreatic Cancer Market Report:
• The Locally Advanced Pancreatic Cancer market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In February 2025, Alpha Tau Medical Ltd. ("Alpha Tau" or the "Company") (NASDAQ: DRTS, DRTSW), the developer of the alpha-radiation cancer therapy Alpha DaRT®, announced that the U.S. Food and Drug Administration (FDA) has approved an Investigational Device Exemption (IDE) supplement. This approval expands the previously announced IDE from January 27, 2025, which authorized a clinical study evaluating Alpha DaRT in combination with first-line chemotherapy for 12 patients with newly diagnosed metastatic pancreatic cancer. The expansion allows the trial to include a broader population of pancreatic cancer patients.
• In January 2025, Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW), the company behind the groundbreaking alpha-radiation cancer therapy Alpha DaRT®, has announced promising interim results from multiple clinical studies. These include safety and feasibility trials for pancreatic cancer treatment, a combination study with pembrolizumab for patients with recurrent, unresectable, or metastatic HNSCC, and additional clinical investigations.
• In December 2024, Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) and Novocure (NASDAQ: NVCR) announced that the Phase 3 PANOVA-3 trial achieved its primary endpoint, showing a statistically significant improvement in median overall survival (mOS) compared to the control group. The study evaluated the efficacy of Tumor Treating Fields (TTFields) therapy in combination with gemcitabine and nab-paclitaxel as a first-line treatment for patients with unresectable, locally advanced pancreatic adenocarcinoma.
• In advanced Locally Advanced Pancreatic Cancer groups, Cantargia AB's CAN04 in combination with gemcitabine/nab-paclitaxel (PDAC) and gemcitabine/cisplatin had early positive activity
• Aggressive tumour growth and a poor prognosis are two common characteristics of pancreatic cancer. Today, pancreatic cancer affects more than 57,600 Americans annually (and double that figure in Europe)
• According to an article titled "Locally Advanced Pancreatic Cancer" by Osipov et al., approximately four out of five patients with pancreatic cancer are diagnosed with locally advanced or metastatic disease that is initially not amenable to surgery. This is due to the lack of screening options and the ambiguity of symptomatology
• Key Locally Advanced Pancreatic Cancer Companies: AstraZeneca, R-Pharm, Hoffmann-La Roche, AB Science, Meabco A/S, Celgene, iOnctura, Tesaro, Inc., FibroGen, SynCore Biotechnology, Jiangsu HengRui Medicine, Biosplice Therapeutics, Eleison Pharmaceuticals, ImmunityBio, Acerta Pharma BV, Salspera LLC, SynerGene Therapeutics, Inc., Merrimack Pharmaceuticals, Rexahn Pharmaceuticals, Inc., and others
• Key Locally Advanced Pancreatic Cancer Therapies: Ixabepilone, Gemcitabine+erlotinib, Masitinib, BP-C1, Gemcitabine, IOA-289, Niraparib, Pamrevlumab, EndoTAG-1 (ET), Fluzoparib, Cirtuvivint, Masitinib, AZD6738, Glufosfamide, PD-L1 t-hank and N-803, ACP-196, Salmonella-IL2, nab-paclitaxel, MM-398, RX-0201 plus Gemcitabine, and others
• The Locally Advanced Pancreatic Cancer epidemiology based on gender analyzed that males are more commonly affected in case of Locally Advanced Pancreatic Cancer than females
• The Locally Advanced Pancreatic Cancer market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Locally Advanced Pancreatic Cancer pipeline products will significantly revolutionize the Locally Advanced Pancreatic Cancer market dynamics.
Locally Advanced Pancreatic Cancer Overview
Locally Advanced Pancreatic Cancer (LAPC) is a stage of pancreatic cancer where the tumor has grown beyond the pancreas and invaded nearby blood vessels or organs but has not yet spread to distant sites (metastasis). Due to its involvement with critical structures, LAPC is often considered inoperable. Treatment typically includes chemotherapy, radiation therapy, or a combination of both to shrink the tumor, manage symptoms, and potentially make surgical removal possible.
Get a Free sample for the Locally Advanced Pancreatic Cancer Market Report:
https://www.delveinsight.com/report-store/locally-advanced-pancreatic-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Locally Advanced Pancreatic Cancer Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Locally Advanced Pancreatic Cancer Epidemiology Segmentation:
The Locally Advanced Pancreatic Cancer market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Locally Advanced Pancreatic Cancer
• Prevalent Cases of Locally Advanced Pancreatic Cancer by severity
• Gender-specific Prevalence of Locally Advanced Pancreatic Cancer
• Diagnosed Cases of Episodic and Chronic Locally Advanced Pancreatic Cancer
Download the report to understand which factors are driving Locally Advanced Pancreatic Cancer epidemiology trends @ Locally Advanced Pancreatic Cancer Epidemiology Forecast
https://www.delveinsight.com/sample-request/locally-advanced-pancreatic-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Locally Advanced Pancreatic Cancer Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Locally Advanced Pancreatic Cancer market or expected to get launched during the study period. The analysis covers Locally Advanced Pancreatic Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Locally Advanced Pancreatic Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Locally Advanced Pancreatic Cancer Therapies and Key Companies
• Ixabepilone: R-Pharm
• Gemcitabine+erlotinib: Hoffmann-La Roche
• Masitinib: AB Science
• BP-C1: Meabco A/S
• Gemcitabine: Celgene
• IOA-289: iOnctura
• Niraparib: Tesaro, Inc.
• Pamrevlumab: FibroGen
• EndoTAG-1 (ET): SynCore Biotechnology
• Fluzoparib: Jiangsu HengRui Medicine
• Cirtuvivint: Biosplice Therapeutics
• Masitinib: AB Science
• AZD6738: AstraZeneca
• Glufosfamide: Eleison Pharmaceuticals
• PD-L1 t-hank and N-803: ImmunityBio
• ACP-196: Acerta Pharma BV
• Salmonella-IL2: Salspera LLC
• nab-paclitaxel: SynerGene Therapeutics, Inc.
• MM-398: Merrimack Pharmaceuticals
• RX-0201 plus Gemcitabine: Rexahn Pharmaceuticals, Inc.
Discover more about therapies set to grab major Locally Advanced Pancreatic Cancer market share @ Locally Advanced Pancreatic Cancer Treatment Market
https://www.delveinsight.com/sample-request/locally-advanced-pancreatic-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Locally Advanced Pancreatic Cancer Market Strengths
• Advancements in computational and bioinformatics platforms and several other R&D practices enable the development of Locally Advanced Pancreatic Cancer
• Strong pipeline activity
Locally Advanced Pancreatic Cancer Market Opportunities
• Rising incidence of cancer will provide a larger window of opportunity for new treatments
• Reoccurrence is very common in cancers even after proper treatment; this opens up a new window for pipeline activity
Scope of the Locally Advanced Pancreatic Cancer Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Locally Advanced Pancreatic Cancer Companies: AstraZeneca, R-Pharm, Hoffmann-La Roche, AB Science, Meabco A/S, Celgene, iOnctura, Tesaro, Inc., FibroGen, SynCore Biotechnology, Jiangsu HengRui Medicine, Biosplice Therapeutics, Eleison Pharmaceuticals, ImmunityBio, Acerta Pharma BV, Salspera LLC, SynerGene Therapeutics, Inc., Merrimack Pharmaceuticals, Rexahn Pharmaceuticals, Inc., and others
• Key Locally Advanced Pancreatic Cancer Therapies: Ixabepilone, Gemcitabine+erlotinib, Masitinib, BP-C1, Gemcitabine, IOA-289, Niraparib, Pamrevlumab, EndoTAG-1 (ET), Fluzoparib, Cirtuvivint, Masitinib, AZD6738, Glufosfamide, PD-L1 t-hank and N-803, ACP-196, Salmonella-IL2, nab-paclitaxel, MM-398, RX-0201 plus Gemcitabine, and others
• Locally Advanced Pancreatic Cancer Therapeutic Assessment: Locally Advanced Pancreatic Cancer current marketed and Locally Advanced Pancreatic Cancer emerging therapies
• Locally Advanced Pancreatic Cancer Market Dynamics: Locally Advanced Pancreatic Cancer market drivers and Locally Advanced Pancreatic Cancer market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Locally Advanced Pancreatic Cancer Unmet Needs, KOL's views, Analyst's views, Locally Advanced Pancreatic Cancer Market Access and Reimbursement
To know more about Locally Advanced Pancreatic Cancer companies working in the treatment market, visit @ Locally Advanced Pancreatic Cancer Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/locally-advanced-pancreatic-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Locally Advanced Pancreatic Cancer Market Report Introduction
2. Executive Summary for Locally Advanced Pancreatic Cancer
3. SWOT analysis of Locally Advanced Pancreatic Cancer
4. Locally Advanced Pancreatic Cancer Patient Share (%) Overview at a Glance
5. Locally Advanced Pancreatic Cancer Market Overview at a Glance
6. Locally Advanced Pancreatic Cancer Disease Background and Overview
7. Locally Advanced Pancreatic Cancer Epidemiology and Patient Population
8. Country-Specific Patient Population of Locally Advanced Pancreatic Cancer
9. Locally Advanced Pancreatic Cancer Current Treatment and Medical Practices
10. Locally Advanced Pancreatic Cancer Unmet Needs
11. Locally Advanced Pancreatic Cancer Emerging Therapies
12. Locally Advanced Pancreatic Cancer Market Outlook
13. Country-Wise Locally Advanced Pancreatic Cancer Market Analysis (2019-2032)
14. Locally Advanced Pancreatic Cancer Market Access and Reimbursement of Therapies
15. Locally Advanced Pancreatic Cancer Market Drivers
16. Locally Advanced Pancreatic Cancer Market Barriers
17. Locally Advanced Pancreatic Cancer Appendix
18. Locally Advanced Pancreatic Cancer Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Latest Reports Offered By DelveInsight:
• Prosthetic Heart Valve Market: https://www.delveinsight.com/report-store/prosthetic-heart-valve-market
• Xerostomia Market: https://www.delveinsight.com/report-store/xerostomia-market
• Cardiac Arrythmia Market: https://www.delveinsight.com/report-store/ambulatory-arrhythmia-monitoring-devices-market
• Alopecia Market: https://www.delveinsight.com/report-store/alopecia-areata-market
• Optical Coherence Tomography Devices Market: https://www.delveinsight.com/report-store/optical-coherence-tomography-oct-devices-market
• Prediabetes Market: https://www.delveinsight.com/report-store/prediabetes-market
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Locally Advanced Pancreatic Cancer Market to Reach New Heights in Growth by 2032, DelveInsight Predicts | AstraZeneca, R-Pharm, Hoffmann-La Roche, AB Science, Meabco A/S, Celgene, iOnctura, Tesaro, Inc., FibroGen, SynCore Biotechnology, Jiangsu HengRui Me here
News-ID: 3879570 • Views: …
More Releases from DelveInsight Business Research
Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals.
Objective of the Case Study
The…
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics.
According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than…
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies.
Biopsy devices play a crucial role in disease diagnosis by…
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide.
DelveInsight's General Surgery Devices Market Report 2032 provides…
More Releases for Locally
Private Therapy in Birmingham: Phinity Therapy Offers Expert Support Locally
Phinity Therapy provides expert support tailored to individual needs, helping clients take charge of their mental health in a way that suits them. Whether you're looking for private therapy near me or more specific support, private therapy in Birmingham offers a wide range of services designed to provide the care and guidance needed for personal growth and healing.
In today's fast-paced world, mental health is more important than ever, and finding…
Communicate Locally with Professional Business Translation Services to Compete G …
If you can't communicate locally, you won't be able to compete globally. It is the first rule of business communication, which helps you position yourself better to do business in communities all over the world. Professional business translation services help you reach out to your target audience in an international market and build meaningful connections without any language barrier.
Semantics is a reputed translation service provider in more than 150 languages…
Arch House Deli – launches range of locally inspired hampers
Arch House Deli (Clifton Village, Bristol, UK) has launched a range of hampers based on food from local producers in Bristol and Bath.
During 2012 the deli has built relationships with local niche food suppliers and has developed a range of hampers selecting the very best from the Bristol and Bath area.
“Our vision for our products is to source local, sustainable, traceable and organic where ever possible. Only if…
Locally Grown South Bay Ballet Closes Successful Season with Cinderella
TORRANCE, CA (May 2012) – Arts enthusiasts can be hard to find in Southern California. Harder still is finding an audience base for ballet. Certainly there are those who snatch-up tickets, and the glamour that comes with, when a world-renowned ballet company makes its way through town. Supporting and nurturing a locally-grown ballet troupe however is a completely different story evidenced by the numerous professional ballet companies…
BluePrint Data Provides Free Locally Installable OEM Internet Filtering Software
OEM Internet Filtering provider and leader in high quality OEM internet content filtering solutions BluePrint Data is expanding its integration tools and utilities with the addition of a locally installable “Content Engine”. The configurable software, provided free by BluePrint Data, enables companies to have a locally installable “URL Lookup” tool for a plethora of devices from local home or small business routers to network gateway appliances or data center…
Locally Made Skincare Products Outperform Major Companies
Customers from around the world write in to share how Natural Family Botanical skincare products have succeeded where store-bought products have failed. G
Merlin, OR - November, 2010 -- Devised with a fresh perspective and all-natural ingredients, there are no better products for sensitive or reactive skin than the formulas of Kelly Frohnauer, founder and owner of Natural Family Botanicals.
Men and women of all ages are discovering their true reflections, free…
